Emerging oral therapies for multiple sclerosis

Bruce Arnold Cohen*, P. Rieckmann

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations

Abstract

Background: Current disease-modifying drugs (DMDs) have positively affected the treatment of relapsing-remitting multiple sclerosis (RRMS); however, the requirement for long-term injections imposes a burden on patients and may lead to reduced adherence in some cases. Furthermore, not all patients respond adequately to current DMDs, suggesting that certain patients require different therapeutic approaches. Therefore, alternative MS treatments with less invasive routes of administration and new modes of action are needed to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efficacy. Discussion: This review discusses the current unmet need for an orally administered treatment for RRMS, including potential benefits of this route of administration, and implications for improved treatment outcomes. Oral drugs that are currently in Phase II/III clinical development are discussed.

Original languageEnglish (US)
Pages (from-to)1922-1930
Number of pages9
JournalInternational Journal of Clinical Practice
Volume61
Issue number11
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Emerging oral therapies for multiple sclerosis'. Together they form a unique fingerprint.

Cite this